| Sep 30 |
AIM ImmunoTech Announces Pricing of $1.26 Million Registered Direct Offering
|
| Sep 27 |
AIM ImmunoTech to Participate in Virtual Investor CEO Connect Segment
|
| Sep 19 |
AIM ImmunoTech sees promising results in Ampligen combo for pancreatic cancer
|
| Sep 19 |
AIM ImmunoTech Reports Positive Preliminary Data in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
|
| Sep 11 |
AIM ImmunoTech Announces that Analysis of AMP-518 Complete Clinical Patient Data Underscores Ampligen’s Potential to Improve the Post-COVID Condition of Fatigue
|
| Aug 20 |
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
|
| Aug 16 |
AIM ImmunoTech Inc. (AIM) Q2 2024 Earnings Call Transcript
|
| Aug 16 |
AIM ImmunoTech GAAP EPS of -$0.03 beats by $0.10
|
| Aug 16 |
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 15 |
AIM ImmunoTech Q2 2024 Earnings Preview
|
